TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.

@article{Danese2006TNFalphaBD,
  title={TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.},
  author={Silvio Danese and Miquel Sans and Franco Scaldaferri and Alessandro Sgambato and Sergio Rutella and Achille Cittadini and Josep Mar{\'i}a Piqu{\'e} and Juli{\'a}n Pan{\'e}s and Jeffry A. Katz and Antonio Gasbarrini and Claudio Fiocchi},
  journal={Journal of immunology},
  year={2006},
  volume={176 4},
  pages={2617-24}
}
The CD40/CD40 ligand (CD40L) pathway is involved in Crohn's disease (CD) pathogenesis. In the patients' circulation, soluble CD40L (sCD40L) levels are elevated and surface CD40L is increased in platelets and T cells, whereas in the intestine CD40 is overexpressed in the microvasculature and CD40L in platelets and T cells. The therapeutic effects of infliximab in CD are attributed to its systemic anti-TNF-alpha action, but because TNF-alpha modulates both CD40 and CD40L, we investigated whether… CONTINUE READING
42 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Similar Papers

Loading similar papers…